Led · Series A · Apr 2026

NeuroClues offers a portable, CE‑marked Class IIa medical device that records high‑speed infrared eye movements and applies proprietary AI algorithms to generate objective neurological biomarkers within minutes. The system is intended for use in hospitals, private neurology practices, and research centers and replaces subjective observational assessments with quantified data that can integrate into clinical workflows. After securing CE certification in early 2025, the company deployed more than 30 devices across seven European countries, including France, Belgium, Italy, Germany, Switzerland, the Netherlands, and the UK. NeuroClues is building clinical partnerships—such as integration into cohorts at the Paris Brain Institute—and is participating in a large-scale study to develop a 25,000-participant normative oculomotor biomarker database. The company aims to enable earlier and more precise identification of neurological conditions including Parkinson’s disease, Alzheimer’s disease, and concussion‑related impairments. Financially, NeuroClues has raised €25 million in total capital to date, including the recent €10 million Series A and additional non‑dilutive funding, and is expanding its commercial organization to support wider European rollout.

Led · Equity · Oct 2024

Minze Health develops digital diagnostics, remote patient monitoring and Prescription Digital Therapeutics (PDTs) for urinary dysfunction and incontinence, including products such as Homeflow and Diary Pod. Its solutions have been used by over 160,000 patients and are trusted by clinicians in 20+ countries. All Minze products are CE‑marked, FDA listed and developed under GDPR and HIPAA regulations. The company plans to commercialize PDTs for lower urinary tract symptoms with initial market focus on Germany and France, leveraging DIGA and PECAN reimbursement schemes. Minze is also driving U.S. market entry for its at‑home diagnostic solutions and plans to increase utilization of Homeflow and Diary Pod in the U.S. To support U.S. commercialization it has appointed a VP Marketing & Sales and intends to establish a U.S. office and team. Minze Health builds hardware and software solutions—including explainable AI-based tools—for screening, diagnostics and remote patient monitoring of lower urinary tract symptoms (LUTS). The company reports deployment across roughly 300 hospitals, urology practices and pelvic floor rehabilitation centers worldwide. Minze frames its addressable population as 2.3 billion people with LUTS, while its CEO referenced an underserved population of approximately 1.5 billion people. Its product combines home medical devices with comprehensive software diagnostics and generates patient-level datasets to enable personalized care from lifestyle advice to digital therapeutics. Proceeds from the recent financing will fund additional clinical studies in Europe and the U.S., execution of the product roadmap, and international B2B/B2C go-to-market expansion. Minze’s stated mission is to bring LUTS diagnostics, treatment and follow-up into patients’ homes to improve accessibility and reduce healthcare costs.

Participated · Equity · Sep 2024

Clouds of Care is a Ghent, Belgium–based MedTech company that develops electrophysiology applications and a comprehensive CNS platform to improve care for people with CNS disorders. Its electrophysiology applications are CE-marked and FDA-cleared for clinicians, and it provides solutions for clinical trials and research. The company holds ISO 13485:2016 and ISO 27001:2013 certifications. Leadership includes Eline Van Vlierberghe (CCO), Gregor Strobbe (co-founder, CEO), Pieter van Mierlo (co-founder, CSO), Jeroen Crappé (COO), Caroline Neuray (CMO), and Tom Van Steenkiste (CTO). Clouds of Care intends to use recent funding to invest in technological infrastructure, expand its team of experts, and deepen research and development. The company also leverages a strategic network of partners to support its platform and care initiatives, and has appointed Michel Vounatsos and Yacine Hadjiat to its board.

Led · Equity · Jul 2024

Bedal International develops and markets FlexGRIP catheter securement devices that help patients safely secure catheters and reduce the risk of complications. The FlexGRIP devices are used hospital‑wide in applications including cancer treatment, post‑operative care and intensive care, and the company recently launched a pediatric product range. Bedal reports its devices are in use in more than 34 countries. The company has offices in Diepenbeek, Belgium and in Anaheim, CA. Bedal closed an $11m funding round and intends to use the funds to expand operations and commercial efforts. The company has stated a particular focus on further growing in the US market.

Participated · Equity · Oct 2022

Intressa Vascular (formerly Cardiatis SA) is a clinical-stage MedTech company based in Gembloux, Belgium. It has developed a proprietary braiding technology platform that produces multilayer stents. Its lead product, the Allay™ Aortic Stent, is designed to treat Type B aortic dissections (TBAD) and residual dissections by recentralizing blood flow inside the true lumen while preserving branch perfusion via a streamlined procedure. The company is led by CEO Pierre Douette and CSO Diane Lejeune. Intressa intends to use recent financing to support clinical development and product registration activities and to further anchor and develop the organization locally. The company recently completed an €18m financing package to advance these objectives.